^
    1year
    A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM). (ASCO 2023)
    PRT811 demonstrated an acceptable safety profile and clinical activity in pts with glioma and MUM. Clinical trial information: NCT04089449.
    Clinical • P1 data
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • PRMT5 (Protein Arginine Methyltransferase 5)
    |
    PRT811
    over1year
    Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review. (PubMed, J Immunother Precis Oncol)
    Partial response has been seen in adenoid cystic carcinoma from both GSK3326595 and JNJ-64619178, with four cases of stable disease seen with PRT543. Highly significant is a durable complete response in isocitrate dehydrogenase 1-mutated glioblastoma multiforme with PRT811...Further studies are warranted, and there are clinical trials to come whose data will be telling of the efficacy of PRMT5 inhibitors in both hematologic and solid malignancies. The aim of this study is to compile available results of PRMT5 inhibitors in oncology clinical trials.
    Review • Journal • IO biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • PRMT5 (Protein Arginine Methyltransferase 5)
    |
    IDH1 mutation
    |
    PRT811 • PRT543 • pemrametostat (GSK3326595) • onametostat (JNJ-64619178)
    over2years
    [VIRTUAL] A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high- grade gliomas (AACR-NCI-EORTC 2021)
    No abstract available
    Clinical • P1 data
    |
    PRMT5 (Protein Arginine Methyltransferase 5)
    |
    PRT811